Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FWBI First Wave BioPharma		$3.28	$2.33 ▼ $60.00	$7.34M	1.28	212,944 shs	56,500 shs
IBIO iBio	$0.85 +6.8%	$0.73	$0.56 ▼ $6.89	$16.61M	0.6	1.39 million shs	945,298 shs
MTNB Matinas Biopharma	$2.16 +1.2%	$1.10	$0.47 ▼ $5.20	$10.96M	1.32	446,664 shs	113,173 shs
NNVC NanoViricides	$1.47 +1.7%	$1.50	$0.94 ▼ $2.07	$23.55M	0.96	241,996 shs	239,572 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FWBI First Wave BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
IBIO iBio	0.00%	+6.72%	+7.90%	-3.30%	-61.03%
MTNB Matinas Biopharma	0.00%	-9.75%	+129.01%	+162.32%	+1,047.01%
NNVC NanoViricides	0.00%	-4.00%	-14.29%	-19.55%	-24.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.8647 of 5 stars	3.5	0.0	0.0	0.0	2.5	0.0	0.6
MTNB Matinas Biopharma	0.6899 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.6
NNVC NanoViricides	0.7253 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FWBI First Wave BioPharma	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	491.72% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
NNVC NanoViricides	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FWBI, NNVC, IBIO, and MTNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	$6.54 per share	N/A
IBIO iBio	$375K	44.29	N/A	N/A	$1.41 per share	0.60
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FWBI First Wave BioPharma	-$15.80M	N/A	0.00	N/A	N/A	N/A	-102.83%	-22.74%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FWBI First Wave BioPharma	0.40	1.21	1.58
IBIO iBio	0.05	1.76	1.76
MTNB Matinas Biopharma	N/A	5.53	5.53
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FWBI First Wave BioPharma	12.30%
IBIO iBio	7.90%
MTNB Matinas Biopharma	11.77%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
FWBI First Wave BioPharma	0.49%
IBIO iBio	0.58%
MTNB Matinas Biopharma	4.60%
NNVC NanoViricides	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FWBI First Wave BioPharma	9	2.48 million	2.46 million	Not Optionable
IBIO iBio	100	19.66 million	9.82 million	N/A
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable

FWBI, NNVC, IBIO, and MTNB Headlines

Recent News About These Companies

NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

August 18, 2025 | proactiveinvestors.com

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

August 18, 2025 | accessnewswire.comA

NanoViricides says antiviral candidate NV-387 could address global measles surge

July 30, 2025 | proactiveinvestors.com

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

July 30, 2025 | accessnewswire.comA

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

July 23, 2025 | proactiveinvestors.com

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

July 23, 2025 | accessnewswire.comA

Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | usatoday.com

NanoViricides says lead antiviral boosted survival in measles-infected mice

July 21, 2025 | proactiveinvestors.com

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | accessnewswire.comA

NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease

July 18, 2025 | pharmabiz.comP

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | azcentral.comA

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

July 16, 2025 | proactiveinvestors.com

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | accessnewswire.comA

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox

July 15, 2025 | finance.yahoo.com

NanoViricides nears completion of clinical trial design for MPox treatment

July 14, 2025 | proactiveinvestors.com

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

July 14, 2025 | markets.businessinsider.com

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

July 7, 2025 | theglobeandmail.com

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox

July 2, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FWBI, NNVC, IBIO, and MTNB Company Descriptions

First Wave BioPharma NASDAQ:FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

iBio NYSE:IBIO

$0.84 +0.05 (+6.83%)

As of 03:46 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Matinas Biopharma NYSE:MTNB

$2.15 +0.03 (+1.17%)

As of 03:46 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

NanoViricides NYSE:NNVC

$1.46 +0.03 (+1.74%)

As of 03:46 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time